Toshifumi Yokota

Toshifumi Yokota
横田俊文
Born
Morioka, Japan
EducationUniversity of Tokyo
Awards
  • Fellow of the Canadian Academy of Health Sciences
  • The Friends of Garrett Cumming Research & Muscular Dystrophy Canada Endowed Research Chair
  • The Henri M. Toupin Chair in Neurological Science
Scientific career
Institutions

Toshifumi (Toshi) Yokota (Japanese: 横田俊文, romanized: Yokota Toshifumi) is a biomedical scientist and professor of medical genetics at the University of Alberta, holding the titles of the Friends of Garrett Cumming Research & Muscular Dystrophy Canada Endowed Research Chair and the Henri M. Toupin Chair in Neurological Science.[1] Yokota is widely recognized for pioneering work in antisense therapy for muscular dystrophy and other genetic diseases, which led to the development of viltolarsen, an FDA-approved treatment for Duchenne muscular dystrophy (DMD).[2][1][3][4] With over 100 peer-reviewed publications and several patents, Yokota has made significant contributions to the field of precision medicine. Yokota also co-edited three volumes in the Methods in Molecular Biology series by Humana Press, Springer-Nature and serves on editorial boards of multiple scientific journals. [5][6][7][8][9][10][11][12][13][14]

In 2023, Yokota was elected as a fellow of the Canadian Academy of Health Sciences, an honor that recognizes outstanding achievements in health sciences. [9] In addition, Yokota serves as Chief Scientific Officer at OligomicsTx, is a co-founder of the Canadian Neuromuscular Network (CAN-NMD), and contributes as a member of the Medical and Scientific Advisory Committee of Muscular Dystrophy Canada. [15][16][17]

  1. ^ a b "FDA approves new drug to treat common form of muscular dystrophy based on research from University of Alberta". MirageNews.com. 9 October 2020. Retrieved 20 August 2021.
  2. ^ Cite error: The named reference :6 was invoked but never defined (see the help page).
  3. ^ "Heroes - Spring 2016". Issuu. 5 May 2016. Retrieved 17 August 2021.
  4. ^ Cite error: The named reference :7 was invoked but never defined (see the help page).
  5. ^ Yokota, Toshifumi; Maruyama, Rika, eds. (2020). Gapmers. Methods in Molecular Biology. Vol. 2176. doi:10.1007/978-1-0716-0771-8. ISBN 978-1-0716-0770-1. ISSN 1064-3745. S2CID 221372639.
  6. ^ Yokota, Toshifumi; Maruyama, Rika, eds. (2018). Exon Skipping and Inclusion Therapies. Methods in Molecular Biology. Vol. 1828. doi:10.1007/978-1-4939-8651-4. ISBN 978-1-4939-8650-7. ISSN 1064-3745. S2CID 52141624.
  7. ^ Maruyama, Rika; Yokota, Toshifumi, eds. (2023). Muscular Dystrophy Therapeutics. Methods in Molecular Biology. Vol. 2587. doi:10.1007/978-1-0716-2772-3. ISBN 978-1-0716-2771-6. ISSN 1064-3745.
  8. ^ "Toshifumi Yokota". scholar.google.com. Retrieved 19 August 2021.
  9. ^ a b "Toshifumi Yokota elected 2023 Fellow of the Canadian Academy of Health Sciences". www.ualberta.ca. Retrieved 17 January 2024.
  10. ^ "International Journal of Molecular Sciences". www.mdpi.com. Retrieved 18 August 2021.
  11. ^ "Genes". www.mdpi.com. Retrieved 18 August 2021.
  12. ^ "Frontiers in Genome Editing". www.frontiersin.org. Retrieved 18 August 2021.
  13. ^ "Nucleic Acid Therapeutics | Mary Ann Liebert, Inc., publishers". home.liebertpub.com. Retrieved 30 May 2022.
  14. ^ "Frontiers in Physiology". www.frontiersin.org. Retrieved 29 June 2022.
  15. ^ "Medical and Scientific Advisory Committee". Muscular Dystrophy Canada. 24 July 2019. Retrieved 31 August 2021.
  16. ^ Cite error: The named reference :9 was invoked but never defined (see the help page).
  17. ^ "Neuromuscular disease network to enhance Canadian research and patient care". www.ualberta.ca. Retrieved 8 September 2021.